Quoin Pharmaceuticals Ltd.
QNRX | NASDAQ
$6.90
-$0.16 (-2.27%)
At close: Sep 21, 2026, 4:00 PM ET
$6.90
$0 (0.00%)
Pre-market:
Sep 22, 2026, 5:01 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -16.29M | -9.53M | -9.38M | -9.26M | -6.06M | -1.67M |
Interest Income | 482.08K | 558.49K | 694.61K | 95.75K | n/a | n/a |
Pretax Income | -15.8M | -8.96M | -8.69M | -9.38M | -21.46M | -2.1M |
Net Income | -15.8M | -8.96M | -8.69M | -9.38M | -21.46M | -2.1M |
Selling & General & Admin | 6.49M | 5.93M | 6.07M | 6.58M | 4.5M | 1.43M |
Research & Development | 9.8M | 3.6M | 3.31M | 2.67M | 1.56M | 244.16K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 16.29M | 9.53M | 9.38M | 9.26M | 6.06M | 1.67M |
Interest Expense | n/a | n/a | n/a | 714.08K | 1.09M | 1.19M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 16.29M | 9.53M | 9.38M | 9.26M | 6.06M | 1.67M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.5M | 133.96K | 25.74K | 403.88K | 1.6K | 20.02K |
Shares Outstanding (Diluted) | 1.5M | 133.96K | 25.74K | 403.88K | 1.6K | 20.02K |
EPS (Basic) | -10.63 | -66.85 | -337.47 | -22.97 | -28.54K | -88.10 |
EPS (Diluted) | -10.63 | -66.85 | -337.47 | -22.97 | -28.54K | -88.10 |
EBITDA | -15.7M | -8.86M | -8.58M | -8.56M | -20.27M | -1.57M |
EBIT | -15.8M | -8.96M | -8.69M | -8.67M | -20.37M | -1.67M |
Depreciation & Amortization | 100K | 100K | 103.71K | 104.04K | 104.04K | 104.04K |
Add to Watchlist
Select watchlists to add or remove QNRX